HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

<ul>
<li>YSB would be added to KraneShares CSI China Internet ETF.Cornerstone investors could opt to cash out directly,taking advantage of improved liquidity, which means even they’re not optimistic about YSB's prospects.</li>
<li>YSB's profit margin is disappointing. It would be hard for YSB to deliver decent profits in the end. This business does not make money. YSB is also short of money.</li>
<li>Since going public, YSB's share price has been on a rollercoaster, which has deviated from the fundamentals, but it should be pointed out eventually stock prices will return to fundamentals.</li>
</ul>


YSB would be added to KraneShares CSI China Internet ETF.Cornerstone investors could opt to cash out directly,taking advantage of improved liquidity, which means even they’re not optimistic about YSB's prospects.
YSB's profit margin is disappointing. It would be hard for YSB to deliver decent profits in the end. This business does not make money. YSB is also short of money.
Since going public, YSB's share price has been on a rollercoaster, which has deviated from the fundamentals, but it should be pointed out eventually stock prices will return to fundamentals.


YSB (9885.HK) - Being Included in ETF Offers a Great Escape Opportunity

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

<ul>
<li>The December rebalance of the <a href="https://www.smartkarma.com/entities/kraneshares-csi-china-internet-etf" target="_blank" data-smartkarma-citation="entities:28208:1" rel="noopener">KraneShares CSI China Internet ETF (KWEB US)</a> will take place at the close of trading on 8 December.</li>
<li>
<a href="https://www.smartkarma.com/entities/fenbi-ltd" target="_blank" data-smartkarma-citation="entities:36640:1" rel="noopener">Fenbi Ltd (2469 HK)</a> and <a href="https://www.smartkarma.com/entities/ysb-inc" target="_blank" data-smartkarma-citation="entities:35982:1" rel="noopener">YSB (9885 HK)</a> will be added to the index and there are no deletions.</li>
<li>There is a big lock-up expiry in <a href="https://www.smartkarma.com/entities/ysb-inc" target="_blank" data-smartkarma-citation="entities:35982:1" rel="noopener">YSB (9885 HK)</a> soon after the index inclusion and this could be an opportunity to access liquidity in the stock.</li>
</ul>


The December rebalance of the KraneShares CSI China Internet ETF (KWEB US) will take place at the close of trading on 8 December.

Fenbi Ltd (2469 HK) and YSB (9885 HK) will be added to the index and there are no deletions.
There is a big lock-up expiry in YSB (9885 HK) soon after the index inclusion and this could be an opportunity to access liquidity in the stock.


KWEB Index Rebalance: Fenbi (2469 HK) & YSB (9885 HK) Added

External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

<ul><li>YSB specializes in providing digital solutions in China’s outside-of-hospital pharmaceutical circulation market.</li><li>According to Frost &amp; Sullivan (F&amp;S), the Company is the largest digital pharmaceutical platform serving businesses outside of hospitals in China, taking a market share of 21.0% in 2022 in terms of GMV (gross merchandise volume).</li><li>YSB’s business model mainly includes Online Marketplace and Self-operation Business (including Targeted Product Launch Business).</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

YSB specializes in providing digital solutions in China’s outside-of-hospital pharmaceutical circulation market.According to Frost &amp; Sullivan (F&amp;S), the Company is the largest digital pharmaceutical platform serving businesses outside of hospitals in China, taking a market share of 21.0% in 2022 in terms of GMV (gross merchandise volume).YSB’s business model mainly includes Online Marketplace and Self-operation Business (including Targeted Product Launch Business).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

YSB (9885 HK) – Digitalizing Outside-Of-Hospital Pharmaceutical Circulation Market in China

APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

WuXi XDC Cayman  / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/wuxi-xdc-cayman-inc" target="_blank" data-smartkarma-citation="entities:39917:1" rel="noopener">WuXi XDC Cayman Inc (1877628D HK)</a> is looking to raise &gt;US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley, Goldman Sachs, and JP Morgan.</li>
<li>WuXi XDC Cayman (WXDC) is a contract research, development, and manufacturing organization (CRDMO) focused on the global antibody drug conjugates (ADC) and broader bioconjugate market providing integrated and end-to-end services.</li>
<li>As per Frost &amp; Sullivan (F&amp;S), the firm was the second largest CRDMO for ADCs and other bioconjugates globally in terms of FY22 sales.</li>
</ul>



WuXi XDC Cayman Inc (1877628D HK) is looking to raise &gt;US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley, Goldman Sachs, and JP Morgan.
WuXi XDC Cayman (WXDC) is a contract research, development, and manufacturing organization (CRDMO) focused on the global antibody drug conjugates (ADC) and broader bioconjugate market providing integrated and end-to-end services.
As per Frost &amp; Sullivan (F&amp;S), the firm was the second largest CRDMO for ADCs and other bioconjugates globally in terms of FY22 sales.


Guangdong Archealth Health Industry Group / Equity Capital Markets

Guangdong Archealth Health Industry Group

<ul>
<li>
<a href="https://www.smartkarma.com/entities/guangdong-archealth-health-industry-group" target="_blank" data-smartkarma-citation="entities:39926:1" rel="noopener">Guangdong Archealth Health Industry Group (GAHI HK)</a> is looking to raise around US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are CICC and ABCI.</li>
<li>Guangdong Archealth Health Industry Group (GAHI) is a digital health management provider.</li>
<li>According to F&amp;S, the firm ranked first in the weight management industry and first in the digital weight management industry in China as per 2022 sales.</li>
</ul>



Guangdong Archealth Health Industry Group (GAHI HK) is looking to raise around US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are CICC and ABCI.
Guangdong Archealth Health Industry Group (GAHI) is a digital health management provider.
According to F&amp;S, the firm ranked first in the weight management industry and first in the digital weight management industry in China as per 2022 sales.


Guangdong Archealth Health Industry Group Tearsheet

China

YSB Inc. operates as a digital pharmaceutical platform outside of hospitals in China.. The Company provides outside of hospital pharmaceutical circulation services. YSB mainly offers services to pharmaceutical companies, distributors, vendors, pharmacies, primary healthcare institutions, and others.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

YSB (9885 HK)

YSB (9885.HK) - Being Included in ETF Offers a Great Escape Opportunity

YSB's being added to KWEB offers a golden opportunity for cornerstone investors to cash out. If these people choose to escape, it's time to...

Xinyao (Criss) Wang

KWEB Index Rebalance: Fenbi (2469 HK) & YSB (9885 HK) Added

Fenbi and YSB will be bought by the KWEB ETF at the close on 8 December. Fenbi also has some passive inflows at month end. YSB has a big lock up...

Brian Freitas

YSB (9885 HK) – Digitalizing Outside-Of-Hospital Pharmaceutical Circulation Market in China

YSB’s business model mainly includes Online Marketplace and Self-operation Business (including Targeted Product Launch Business).

CMB International

WuXi XDC Cayman Pre-IPO Tearsheet

WuXi XDC Cayman Inc (1877628D HK) is looking to raise >US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley,...

Clarence Chu

Guangdong Archealth Health Industry Group Tearsheet

Guangdong Archealth Health Industry Group (GAHI HK) is looking to raise around US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal...

Clarence Chu

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)